格隆汇9月26日｜港股市场药品股普跌，其中，康龙化成(300759)、恒瑞医药(600276)、百济神州跌超 3%，药明生物、泰格医药(300347)、康方生物等跌超2%。当地时间9月25日，美国总统特朗普宣布，自 10月1日起，美国将对多类进口产品实施新一轮高额关税，其中对任何品牌或专利的医药产品征收100% 的关税。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

港股市场药品股普跌，其中，康龙化成、恒瑞医药、百济神州跌超3%，药明生物、泰格医药、康方生 物等跌超2%。当地时间9月25日，美国总统特朗普宣布，自10月1日起，美国将对多类进口产品实施新 一轮高额关税，其中对任何品牌或专利的医药产品征收100%的关税。 ...

Core Viewpoint - The article discusses the evolving landscape of the Chinese innovative drug market, emphasizing the significance of business development (BD) transactions as a driving force behind the recent bull market in innovative drugs. However, it warns that the overemphasis on BD may lead to a shift in investment logic as the market matures [1][2]. Group 1: BD Transactions and Market Dynamics - BD expectations have been a core driver of the recent bull market in innovative drugs, significantly increasing the market capitalization of many pharmaceutical companies [2]. - As the number and value of BD transactions rise, investor decision thresholds are also increasing, leading to a potential devaluation of BD's perceived value in investment decisions [2]. - The article suggests that while BD will continue to be important, its dominance as the primary investment logic will gradually diminish, necessitating a new consensus among investors [2]. Group 2: Commercialization and Market Potential - The commercialization of drugs is crucial for innovative pharmaceutical companies, especially in the context of limited funding and high R&D costs. Many companies rely on BD as a financing method due to the challenges in securing capital [4]. - The domestic market remains a critical area for commercialization, despite some investors viewing it pessimistically. The article argues that successful commercialization in the domestic market can significantly alleviate R&D pressures for companies [5][6]. - There is a notable discrepancy between the overemphasis on BD expectations and the undervaluation of commercialization potential, particularly in the domestic market, which is deemed unreasonable [6]. Group 3: Future Investment Trends - The article posits that the next wave of investment in the pharmaceutical sector may focus on companies that are successfully commercializing their products in the domestic market, rather than solely on BD opportunities [6][7].

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The adjustment of medical insurance and commercial insurance directories is accelerating, suggesting a favorable environment for undervalued quality stocks during market corrections [4][5] - The report emphasizes the importance of timing and stock selection in the current market, particularly after a broad rally in innovative drug stocks [4] - The upcoming ESMO conference in October is highlighted as a key event, with specific companies recommended for attention due to potential significant data releases [4] Summary by Sections Market Performance - The Hang Seng Index fell by 1.1% and the Hang Seng Healthcare Index decreased by 1.4% during the week of September 16-23, 2025, ranking 5th among 12 industry indices [4][6] - Sub-industry performance varied, with Internet medicine showing a slight increase of 0.9%, while sectors like medical devices and hospitals saw declines of 5.2% and 8.2%, respectively [4][6] Valuation Overview - The report provides a detailed valuation summary for various companies, with notable price-to-earnings (P/E) ratios for the pharmaceutical sector, such as 31.0x for prescription drugs and 14.1x for biopharmaceuticals [15] - The average P/E ratio across the sector is reported at 57.0, indicating a diverse valuation landscape [3] Institutional Holdings - As of September 23, 2025, domestic institutional holdings through Hong Kong Stock Connect remained stable at 22.2%, while foreign holdings slightly decreased to 38.7% [34][38] - The report notes a trend of increased foreign investment in innovative drug companies, with specific companies like InnoCare and Legend Biotech seeing significant increases in holdings [38][40] Regulatory Developments - The report discusses the recent adjustments to the national basic medical insurance directory and commercial insurance innovative drug directory, with a low approval rate for submitted drugs [5] - The 11th batch of national drug procurement has been announced, with new rules aimed at stabilizing clinical practices and ensuring quality [5]

恒生港股通创新药指数通过在编制方案中剔除CXO，成为ETF跟踪的指数中首批"纯度"100%的创新药 指数，更加精准地反映我国创新药企的整体表现。目前，恒生创新药ETF（159316）是市场唯一跟踪该 指数的产品，可助力投资者精准布局创新药产业发展机遇。 昨日，恒瑞医药宣布与全球制药公司Glenmark达成独家许可协议，将其自主研发的HER2 ADC药物瑞康 曲妥珠单抗(1811)在除中、美、欧、日等核心市场外的全球权益授权给Glenmark，并收取1800万美元首 付款及最高10.93亿美元的潜在里程碑付款。 有分析认为，恒瑞医药HER2 ADC药物的海外授权交易证明中国创新药企已具备全球竞争力，此次交易 打破了近期创新药板块缺乏BD事件催化的平淡局面，加之即将到来的欧洲肿瘤内科学会及第四季度传 统BD交易高频期，市场对后续BD事件预期升温，有望开启新一轮创新药行情。 港股创新药板块午后维持红盘震荡，截至14:45，恒生港股通创新药指数上涨0.6%，云顶新耀涨超5%， 乐普生物-B涨超3%，康方生物、恒瑞医药等多股涨超1%，此前连续3日"吸金"的恒生创新药ETF （159316）盘中再获2100万份净申购。 ...

Core Insights - The healthcare indices in Hong Kong have shown positive performance, with the Hang Seng Healthcare Index rising by 0.67% and the Hang Seng Innovation Drug Selection Index increasing by 0.74% as of September 25, 2025 [3][5] - Notable stock performances include a 6.57% increase in Crystal Technology Holdings and a 6.41% rise in Junshi Biosciences [3][5] - The liquidity of the ETFs tracking these indices is robust, with significant trading volumes and turnover rates [3][5][7] ETF Performance - The Hang Seng Healthcare ETF (513060) has seen a 27.42% increase over the past three months, ranking in the top third among comparable funds [3] - The Hong Kong Innovation Drug Selection ETF (520690) has recorded a 2.63% increase since its inception [5] - The Medical 50 ETF (159838) has increased by 2.19% over the past month, ranking in the top half among comparable funds [7] Company Developments - Heng Rui Medicine has entered an overseas licensing agreement with Glenmark for the drug Rukang Qumai (HER2 ADC), which includes an upfront payment of $18 million and potential milestone payments and sales royalties totaling nearly $1.1 billion, indicating international recognition of its ADC products [7][8] - The National Healthcare Security Administration is actively seeking information on innovative medical consumables such as brain-computer interfaces and surgical robots, aiming to accelerate the coding process for medical insurance and support the commercialization of innovative medical devices [7][8] Market Sentiment - The dual boost from the international licensing agreement and proactive government engagement in innovative technologies is expected to enhance sentiment in the healthcare sector, particularly for companies with technological barriers in ADCs, surgical robots, and brain-computer interfaces [8]

Group 1 - The Hong Kong stock market's innovative drug sector has seen significant gains since the beginning of the year, with multiple indices rising over 100% [1] - Recently, the Hang Seng Pharmaceutical ETF (159892) has experienced a slight pullback from its recent highs, indicating a shift in market focus towards AI [1] - On September 25, the Hang Seng Pharmaceutical ETF briefly rose over 1%, with leading stocks such as Crystal Technology Holdings, BeiGene, and CanSino Biologics showing strong performance [1] Group 2 - Crystal Technology Holdings, a representative stock in the AI medical field, has shown continuous upward movement, rising for four consecutive days and achieving over 100% growth year-to-date [1] - Market opinions suggest that as supply continues to proliferate and iterate, many AI medical companies are still positioned relatively low, indicating potential for improvement in their core business performance [1] - The Hong Kong Stock Connect Medical ETF (520510) tracks the Hong Kong Stock Connect Medical Theme Index, holding stocks like WuXi Biologics, Alibaba Health, JD Health, and Crystal Technology Holdings, focusing on AI medical and CXO themes [1]

Core Viewpoint - The Chinese pharmaceutical industry is experiencing a significant transformation driven by technological breakthroughs and demographic changes, leading to a shift from a reliance on license-in to license-out strategies, positioning Chinese companies as key players in the global market [2][4][11]. Group 1: Industry Trends - The Hong Kong pharmaceutical sector is witnessing a surge, with ETFs tracking the Hang Seng Biotechnology Index showing strong performance, indicating a structural change in the industry [1][3]. - Innovation drugs are becoming a major investment theme for 2025, with significant year-to-date gains in related indices, highlighting the leading role of companies like WuXi Biologics and BeiGene [4][5]. - The Chinese pharmaceutical industry now ranks second globally, with approximately 30% of innovative drugs under development worldwide, and a notable increase in the approval rate of new drugs [8][9]. Group 2: Technological Advancements - The advent of CRISPR gene editing and AI technologies is revolutionizing drug development, significantly reducing research and development cycles and enhancing the capabilities of Chinese pharmaceutical companies [2][7]. - The emergence of platform technologies such as ADCs, bispecific antibodies, and cell therapies is opening new avenues for drug development, contributing to the increased competitiveness of domestic biotech products [7]. Group 3: Market Dynamics - The market is currently experiencing a revaluation of innovative drug companies, with many leading firms turning profitable and their valuations being reassessed positively [7][11]. - The increase in license-out transactions indicates a shift in the global innovation chain, with Chinese companies now accounting for over 51% of the total transaction value in the BD market [11]. Group 4: Policy and Financial Environment - Supportive policies, including stable medical insurance negotiations and expedited drug approval processes, are fostering an environment conducive to innovation [8]. - The easing of monetary policy, including interest rate cuts by the Federal Reserve, is providing a favorable financing environment for biotech companies, further enhancing their growth prospects [8]. Group 5: Investment Opportunities - The Hang Seng Medical ETF and the Hong Kong Stock Connect Medical ETF are emerging as attractive investment vehicles, providing exposure to core assets in the Hong Kong pharmaceutical sector [3][15]. - The recent restructuring of the Hang Seng Biotechnology Index has improved its focus on leading companies in the biotech field, enhancing its investment appeal [14][15].

Group 1 - A-shares in the innovative drug sector experienced a strong rebound, with the only drug ETF (562050) rising by 2.18%, ending a three-day decline [1][5] - Key stocks such as Ganli Pharmaceutical and Xinlitai reached their daily limit up, with Ganli Pharmaceutical's stock price hitting a historical high [1][5] - The medical device sector also showed recovery, with the largest medical ETF (512170) increasing by 1.58%, ending a four-day decline [1][5] Group 2 - The Hong Kong innovative drug sector continued to show weakness, with major stocks like Kangfang Biotech and Sanofi falling over 2%, and the Hong Kong innovative drug ETF (520880) declining by 0.64% [3][5] - Despite the mixed performance, the overall sentiment remains positive, driven by multiple favorable factors including significant agreements and policy support [5][6] - Ganli Pharmaceutical signed a 3 billion yuan supply framework agreement for insulin in Brazil, and Xinlitai made substantial progress with its innovative drug pipeline [5][6] Group 3 - The upcoming peak period for innovative drug business development transactions is expected to bring significant deals in October and November [6] - Fund managers maintain a positive outlook on the pharmaceutical sector, suggesting a balanced investment strategy across various segments including medical devices and services [6][7] - The medical ETF market remains robust, with the largest medical ETF (512170) having a scale of 26.5 billion yuan, indicating strong investor interest [8]

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **Chinese innovative drug industry** and its current trends, particularly focusing on the **CRO (Contract Research Organization)** and **CDMO (Contract Development and Manufacturing Organization)** sectors [1][3][13]. Core Insights and Arguments - **Valuation Trends**: The valuation of Chinese innovative drugs is currently lower than historical peaks, with a static PS (Price to Sales) ratio around 7 times, compared to a high of 9.3 times. However, due to global competitiveness, the theoretical static PS is expected to exceed previous levels, driven by significant product cycles [2][4]. - **BD Activity**: There has been a surge in business development (BD) transactions among domestic innovative drug companies, with upfront payments in the first nine months of the year reaching **6.58 billion yuan**, surpassing the total of **6 billion yuan** for the entire previous year. The total transaction amount also exceeded **56.4 billion yuan** compared to **48.9 billion yuan** last year [4]. - **Immunotherapy and ADC Developments**: Chinese companies are showing strong global competitiveness in the dual-antibody sector, with significant clinical advancements. For instance, **AK12** from Kangfang Biotech has multiple ongoing Phase III trials, and **IBI363** from Innovent has received FDA approval for a global Phase III study in lung cancer [5][6]. - **Weight Loss Sector**: The weight loss sector is highlighted as a competitive area, with promising data from Eli Lilly's oral GLP-1 molecule, **ofgliprant**, providing opportunities for Chinese companies to improve their offerings [8][10]. Additional Important Insights - **CRO and CDMO Recovery**: The CRO industry has moved past its most challenging period, with increased investment activity and a recovery in overseas demand for Chinese CDMO companies. Key players such as WuXi AppTec and Tigermed are recommended for attention [3][13]. - **Upstream Pharmaceutical Chain Recovery**: There are signs of recovery in the upstream pharmaceutical supply chain, particularly in R&D, with companies like **BaiPuSiSi** experiencing a resurgence in market demand [14]. - **Global Competitiveness Strategies**: Chinese innovative drug companies are encouraged to enhance their global competitiveness through overseas sales, R&D, and potential licensing opportunities. Companies like BeiGene and Legend Biotech are highlighted for their performance in this regard [12]. Conclusion The conference call provides a comprehensive overview of the current state and future prospects of the Chinese innovative drug industry, emphasizing the importance of global competitiveness, active BD transactions, and the recovery of the CRO and CDMO sectors. The insights presented indicate a positive outlook for the industry, driven by innovation and strategic partnerships.